Aesthetic and dental category expansion — September 12, 2026

Checked and integrated: 2026-09-12T22:25:25Z. Six new categories and two existing-topic expansions; twenty-five active categories total. This was not a full refresh of the original nineteen categories.

Scope expansion: add all six proposed aesthetic areas, cellulite and hair graying; explicitly include dental alignment. Worldwide human studies at all phases, U.S. availability emphasis, devices/procedures and labeled rumors remain in scope.

Coverage and starting findings

Skin aging, laxity and regeneration

Topic notes. Early KB304 gene-therapy signal; established retinoid evidence and newer device comparisons. Visible tightening and long-term safety remain distinct from collagen claims.

Next: KB304 Phase 2 start targeted 2027 (August 2026 sponsor forecast); no reliable readout date. Device comparisons and FDA RF-microneedling review undated.

Limits: ClinicalTrials.gov detailed pages and API incompletely retrievable; PEARL-2 design/results verified from sponsor primary reports, not a fresh complete registry-status read. No definitive readout date verified for device/topical subtracks; selective baseline did not establish a specific new rumor.

Scar prevention, treatment and stretch marks

Topic notes. Early human antifibrotic programs; verteporfin recruitment records need refresh; stretch-mark combination evidence is modest and mixed.

Next: SNT-9465 recruitment targeted Q3 2026 and topline during 2026 (sponsor forecasts); verteporfin and stretch-mark readouts have no dependable near-term dates.

Limits: NCT07488988 primary record did not yield readable details; verify before using mirrored trial status or dates. SNT-9465 and SATELLITE primary registry identifiers not independently matched. No exhaustive informal-source sweep; verteporfin Geneva record is stale.

Facial volume restoration and contour

Topic notes. Sculptra plus Restylane after weight loss has peer-reviewed uncontrolled evidence; new filler indications and better fat-graft retention remain active questions.

Next: No reliable pivotal readout or U.S. decision date verified; watch comparative post-weight-loss trials, longer follow-up and indication-specific approvals.

Limits: Direct ClinicalTrials.gov/API retrieval incomplete; primary paper establishes completed follow-up without asserting fresh registry fields. No specific new rumor or dated next pivotal readout was established in this selective baseline.

Pigmentation and uneven skin tone

Topic notes. New melasma/topical evidence with small or mixed effects; approved topical vitiligo therapy and positive oral-JAK Phase3 topline.

Next: Povorcitinib additional vitiligo data H2 2026 and filings H1 2027 (April sponsor guidance); no firm next malassezin/thiamidol milestone.

Limits: Malassezin full methodology not retrieved; primary abstract reviewed. Direct current registry recruitment fields not comprehensively retrieved. No exhaustive informal-source sweep; no new firm PIH/solar-spot readout date identified.

Acne and rosacea

Topic notes. Sanofi acne vaccine remains in Phase 1/2; newer approved rosacea therapy has comparative evidence; DMT310 prescription development changed direction.

Next: No dependable near-term readout date verified; reconcile SP0268 registry timing and watch initial efficacy, durability and new trial announcements.

Limits: SP0268 live registry/API inaccessible; current sponsor recruitment readable but completion date unresolved. Selective baseline; no appraised acne/rosacea rumor entry.

Dental alignment, regeneration and repair

Topic notes. Orthodontic advances require whole-course and retention outcomes; early enamel-repair evidence and a congenital tooth-regeneration program are included.

Next: TRG035 Phase IIa enrollment/dosing after August 2026 trial review; no firm dental readout date verified. Several orthodontic registry statuses need refreshing.

Limits: Selective baseline; live orthodontic registry/API statuses and completion estimates inaccessible. No verified result date for dental programs; exact U.S. availability of investigational/new formulations requires product-specific review.

Localized fat removal and cellulite

Topic notes. Cellulite subtopic adds cleared septal release and injectable evidence, with smoothing separate from fat loss.

Next: Cellulite: no firm next readout verified; watch comparative and longer-term evidence and CBL-514 follow-on studies.

Limits: Bounded cellulite expansion only; parent fat-removal programs not fully rechecked. No firm future readout verified; informal sources not exhaustively appraised.

Hair loss, restoration and graying

Topic notes. Hair-graying subtopic added; human evidence is limited and BioQ BQ-002 is an unverified-human-stage lead.

Next: Hair graying: no firm date verified. BQ-002 Phase 1 in 2027 is an explicitly unconfirmed Reddit claim, not official guidance.

Limits: Bounded hair-graying expansion only; existing hair-loss programs not rechecked. No matched BQ-002 human trial or official timing verified.

Preservation and validation

The original topic histories, prior event records, rumor policy and full-topic successful-check timestamps were retained. New baselines use this integration timestamp; cellulite and hair-graying checks are recorded as bounded scope expansions. Initial brief, cover, watchlist and state were reconciled before the scheduled-task update.

Scheduled-task verification

Updated the existing therapy-and-screening-watch heartbeat through the scheduled-task tool. Its saved prompt was read back and matches the prepared twenty-five-category scope, including dental alignment and the two subtopics. Active status, Tuesday/Friday 9 a.m. Eastern schedule, destination task and original creation record are preserved. Rumor handling and meaningful-change-only notifications remain intact. All twenty-five index entries, baseline sections and topic paths were checked; no broken internal links were found.